Q2 2025 Management View Punit S. Dhillon, President and CEO, highlighted the imminent reporting of Phase IIa data for ...

Skye Bioscience Inc (SKYE) reports significant advancements in clinical trials and financial stability, despite increased ...

Reiterate top-line data readout from CBeyond™ Phase 2a study of nimacimab planned late Q3/early Q4 2025Patient enrollment in ...

Given this risk, we thought we'd take a look at whether Skye Bioscience (NASDAQ:SKYE) shareholders should be worried about its cash burn. For the purposes of this article, cash burn is the annual rate ...

View the latest Skye Bioscience Inc. (SKYE) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Learn about the executive team and board of directors at Skye Bioscience Inc Ordinary Shares (SKYE:XNAS) and review their bios and compensation over the latest fiscal years.

Skye Bioscience Inc is listed on the CBOE trading with ticker code SKYE.US. It has a market capitalisation of $124.21m, with approximately 30.97m shares in issue. Over the last year, Skye ...

Q2 2025 has demonstrated the pharmaceutical industry’s continued momentum in developing transformative therapies across ...

Detailed price information for Skye Bioscience Inc (SKYE-Q) from The Globe and Mail including charting and trades.

Skye Bioscience has an analyst consensus of Strong Buy, with a price target consensus of $17.20, implying a 254.6% upside from current levels. In a report issued on June 24, Citizens JMP also ...